A phase i study of the oral platinum agent satraplatin in sequential combination with capecitabine in the treatment of patients with advanced solid malignancies

Elisa Gallerani, Jean Bauer, Dagmar Hess, Steffen Boehm, Cornelia Droege, Sandrine Jeckelmann, Monica Miani, Richard Herrmann, Silvia Marsoni, Sabine Sperka, Cristiana Sessa

Research output: Contribution to journalArticle

Abstract

Background. The broad spectrum of antitumor activity of both the oral platinum analogue satraplatin (S) and capecitabine (C), along with the advantage of their oral administration, prompted a clinical study aimed to define the maximum tolerated dose (MTD) of the combination. Patients and methods. Four dose levels of S (mg/m2/day) and C (mg/m2/day) were evaluated in adult patients with advanced solid tumors: 60/1650, 80/1650, 60/2000, 70/2000; a course consisted of 28 days with sequential administration of S (days 15) and C (days 821) followed by one week rest. Results. Thirty-seven patients were treated, 24 in the dose escalation and 13 in the expansion phase; at the MTD, defined at S 70/C 2000, two patients presented dose limiting toxicities: lack of recovery of neutropenia by day 42 and nausea with dose skip of C. Most frequent toxicities were nausea (57%), diarrhea (51%), neutropenia (46%), anorexia, fatigue, vomiting (38% each). Two partial responses were observed in platinum sensitive ovarian cancer and one in prostate cancer. Conclusion. At S 70/C 2000 the combination of sequential S and C is tolerated with manageable toxicities; its evaluation in platinum and fluorouracil sensitive tumor types is worthwhile because of the easier administration and lack of nephro- and neurotoxicity as compared to parent compounds.

Original languageEnglish
Pages (from-to)1105-1110
Number of pages6
JournalActa Oncologica
Volume50
Issue number7
DOIs
Publication statusPublished - Oct 2011

ASJC Scopus subject areas

  • Oncology
  • Radiology Nuclear Medicine and imaging
  • Hematology

Fingerprint Dive into the research topics of 'A phase i study of the oral platinum agent satraplatin in sequential combination with capecitabine in the treatment of patients with advanced solid malignancies'. Together they form a unique fingerprint.

  • Cite this

    Gallerani, E., Bauer, J., Hess, D., Boehm, S., Droege, C., Jeckelmann, S., Miani, M., Herrmann, R., Marsoni, S., Sperka, S., & Sessa, C. (2011). A phase i study of the oral platinum agent satraplatin in sequential combination with capecitabine in the treatment of patients with advanced solid malignancies. Acta Oncologica, 50(7), 1105-1110. https://doi.org/10.3109/0284186X.2010.543697